Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.
Market Analysis and Insights: Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is projected to reach US$ 1496.7 million by 2026, from US$ 1294.1 million in 2020, at a CAGR of 14.9%% during 2021-2026.
Global Circulating Tumor Cells (CTCs) Prognostic Technologies Scope and Market Size
Circulating Tumor Cells (CTCs) Prognostic Technologies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Type
Tumor Cell Enrichment
Tumor Cell Detection
Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Market Analysis and Insights: Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market size is projected to reach US$ 1496.7 million by 2026, from US$ 1294.1 million in 2020, at a CAGR of 14.9%% during 2021-2026.
Global Circulating Tumor Cells (CTCs) Prognostic Technologies Scope and Market Size
Circulating Tumor Cells (CTCs) Prognostic Technologies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The following players are covered in this report:
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Type
Tumor Cell Enrichment
Tumor Cell Detection
Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue
1.4 Market by Type
1.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tumor Cell Enrichment
1.4.3 Tumor Cell Detection
1.5 Market by Application
1.5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application: 2020 VS 2026
1.5.2 Prostate Cancer
1.5.3 Breast Cancer
1.5.4 Colorectal Cancer
1.5.5 Lung Cancer
1.5.6 Ovarian Cancer
1.5.7 Pancreatic Cancer
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Perspective (2015-2026)
2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Growth Trends by Regions
2.2.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Share by Regions (2015-2020)
2.2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Strategy
2.3.6 Primary Interviews with Key Circulating Tumor Cells (CTCs) Prognostic Technologies Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Market Size
3.1.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Revenue (2015-2020)
3.1.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Players (2015-2020)
3.1.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio
3.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2019
3.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players Head office and Area Served
3.4 Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
3.5 Date of Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Type (2015-2020)
4.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
5.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
6.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in North America (2019-2020)
6.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
6.4 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
7.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Europe (2019-2020)
7.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
7.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
8 China
8.1 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
8.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in China (2019-2020)
8.3 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
8.4 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
9 Japan
9.1 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
9.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Japan (2019-2020)
9.3 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
9.4 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
10.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
10.4 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
11 India
11.1 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
11.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in India (2019-2020)
11.3 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
11.4 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
12.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Central & South America (2019-2020)
12.3 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
12.4 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AdnaGen
13.1.1 AdnaGen Company Details
13.1.2 AdnaGen Business Overview
13.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.1.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020))
13.1.5 AdnaGen Recent Development
13.2 ACDBio
13.2.1 ACDBio Company Details
13.2.2 ACDBio Business Overview
13.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.2.4 ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.2.5 ACDBio Recent Development
13.3 Celula
13.3.1 Celula Company Details
13.3.2 Celula Business Overview
13.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.3.4 Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.3.5 Celula Recent Development
13.4 Epic Sciences
13.4.1 Epic Sciences Company Details
13.4.2 Epic Sciences Business Overview
13.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.4.4 Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.4.5 Epic Sciences Recent Development
13.5 Fluxion Biosciences
13.5.1 Fluxion Biosciences Company Details
13.5.2 Fluxion Biosciences Business Overview
13.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.5.4 Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.5.5 Fluxion Biosciences Recent Development
13.6 Rarecells
13.6.1 Rarecells Company Details
13.6.2 Rarecells Business Overview
13.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.6.4 Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.6.5 Rarecells Recent Development
13.7 Silicon Biosystems
13.7.1 Silicon Biosystems Company Details
13.7.2 Silicon Biosystems Business Overview
13.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.7.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.7.5 Silicon Biosystems Recent Development
13.8 Vitatex
13.8.1 Vitatex Company Details
13.8.2 Vitatex Business Overview
13.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.8.4 Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.8.5 Vitatex Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue
1.4 Market by Type
1.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tumor Cell Enrichment
1.4.3 Tumor Cell Detection
1.5 Market by Application
1.5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Application: 2020 VS 2026
1.5.2 Prostate Cancer
1.5.3 Breast Cancer
1.5.4 Colorectal Cancer
1.5.5 Lung Cancer
1.5.6 Ovarian Cancer
1.5.7 Pancreatic Cancer
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Perspective (2015-2026)
2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Growth Trends by Regions
2.2.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Share by Regions (2015-2020)
2.2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Strategy
2.3.6 Primary Interviews with Key Circulating Tumor Cells (CTCs) Prognostic Technologies Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Market Size
3.1.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Revenue (2015-2020)
3.1.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Players (2015-2020)
3.1.3 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio
3.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2019
3.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players Head office and Area Served
3.4 Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
3.5 Date of Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Type (2015-2020)
4.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
5.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
6.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in North America (2019-2020)
6.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
6.4 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
7.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Europe (2019-2020)
7.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
7.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
8 China
8.1 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
8.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in China (2019-2020)
8.3 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
8.4 China Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
9 Japan
9.1 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
9.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Japan (2019-2020)
9.3 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
9.4 Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
10.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
10.4 Southeast Asia Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
11 India
11.1 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
11.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in India (2019-2020)
11.3 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
11.4 India Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2015-2020)
12.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players in Central & South America (2019-2020)
12.3 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Type (2015-2020)
12.4 Central & South America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AdnaGen
13.1.1 AdnaGen Company Details
13.1.2 AdnaGen Business Overview
13.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.1.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020))
13.1.5 AdnaGen Recent Development
13.2 ACDBio
13.2.1 ACDBio Company Details
13.2.2 ACDBio Business Overview
13.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.2.4 ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.2.5 ACDBio Recent Development
13.3 Celula
13.3.1 Celula Company Details
13.3.2 Celula Business Overview
13.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.3.4 Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.3.5 Celula Recent Development
13.4 Epic Sciences
13.4.1 Epic Sciences Company Details
13.4.2 Epic Sciences Business Overview
13.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.4.4 Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.4.5 Epic Sciences Recent Development
13.5 Fluxion Biosciences
13.5.1 Fluxion Biosciences Company Details
13.5.2 Fluxion Biosciences Business Overview
13.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.5.4 Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.5.5 Fluxion Biosciences Recent Development
13.6 Rarecells
13.6.1 Rarecells Company Details
13.6.2 Rarecells Business Overview
13.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.6.4 Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.6.5 Rarecells Recent Development
13.7 Silicon Biosystems
13.7.1 Silicon Biosystems Company Details
13.7.2 Silicon Biosystems Business Overview
13.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.7.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.7.5 Silicon Biosystems Recent Development
13.8 Vitatex
13.8.1 Vitatex Company Details
13.8.2 Vitatex Business Overview
13.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
13.8.4 Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2015-2020)
13.8.5 Vitatex Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
